NCT05941819

Brief Summary

The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury. Participants will be implanted with the ARC-IM Thoracic System which aim to deliver, at the low thoracic level, targeted epidural electrical stimulation that will support natural hemodynamic control.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 4, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 12, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

September 5, 2023

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

November 1, 2023

Status Verified

October 1, 2023

Enrollment Period

2.1 years

First QC Date

July 4, 2023

Last Update Submit

October 31, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Occurence of Serious Adverse Event and Adverse Events that are deemed related or possibly related to the study procedure or to the ARC-IM Thoracic System

    Assess the safety of ARC-IM Therapy at supporting the management of hemodynamic instability with sub-acute or chronic spinal cord injury suffering from orthostatic hypotension

    Throughout study, average of 15.5 months

Study Arms (1)

All participants

EXPERIMENTAL

All participants will be provided with the ARC-IM Thoracic System (implantable and non-implantable parts)

Device: ARC-IM Thoracic System implantation

Interventions

Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region

All participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Must provide and sign the Informed Consent prior to any study-related procedures
  • Traumatic Spinal Cord Injury
  • Spinal cord injury lesion level between C3 and T6 (inclusive)
  • AIS- A, B, C or D
  • SCI ≥ 1month
  • Confirmed orthostatic hypotension
  • Stable medical, physical and psychological condition as considered by the investigators
  • Able to understand and interact with the study team in Dutch or English
  • Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments
  • In case participants need continuous support from a personal caregiver in daily life, then the presence of their caregiver during the visits to the study site is needed, including independent transport (not dependent on a cab)

You may not qualify if:

  • Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery
  • Diseases and conditions that would require regular MRI
  • The inability to perform an MRI due to metal, magnetic or electrical device in the body (e.g. oral implant with magnet, mtal splinter, neurostimulator, artificial heart valve, clips, stents...) as assessed by the MRI form of Sint Maartenskliniek
  • The inability to withhold antiplatelet/anticoagulation agents perioperatively
  • History of myocardial infarction or cerebrovascular event within the past 6 months
  • Other conditions that would make the subject unable to participate in testing in the judgement of the investigators
  • Clinically significant mental illness in the judgement of the investigators
  • Botulinum toxin non-vesical and vesical injections in the previous 3 months before the enrolment
  • Presence of significant pressure ulcers
  • Recurrent urinary tract infection refractory to antibiotics
  • Presence of indwelling baclofen (e.g. intrathecal baclofen pump) or insulin pump
  • Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding
  • Lack of safe contraception for women of childbearing capacity
  • Intention to become pregnant during the course of the study,
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sint Maartenskliniek

Ubbergen, 6574NA, Netherlands

RECRUITING

MeSH Terms

Conditions

Spinal Cord InjuriesHypotension, Orthostatic

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesOrthostatic IntolerancePrimary DysautonomiasAutonomic Nervous System DiseasesHypotensionVascular DiseasesCardiovascular Diseases

Study Officials

  • Ilse Van Nes, MD, PhD

    Sint Maartenskliniek, department of rehabilitation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2023

First Posted

July 12, 2023

Study Start

September 5, 2023

Primary Completion

September 30, 2025

Study Completion

September 30, 2025

Last Updated

November 1, 2023

Record last verified: 2023-10

Locations